机构外周血管升压药方案偏离的描述性概述及其在学术医疗系统中的安全性影响
该回顾性观察研究纳入学术医疗系统10家医院2020年10月至2023年5月接受血管升压药输注的成人患者,评估外周血管升压药方案偏离及外渗事件。79.4%偏离因休克恶化等待中心通路。10例(13.7%)发生外渗,3例需酚妥拉明治疗;源人群二次分析中47/3518例(1.3%)因外周升压药外渗接受酚妥拉明,其中72.4%在外渗时方案一致。结论认为临床显著外渗不常见,多数治疗的外渗发生于方案一致患者,支持外周升压药总体安全性。
要点
- 79.4%的偏离发生在休克恶化、等待中心静脉通路期间。
- 确认偏离患者中外渗10例(13.7%),3例需酚妥拉明治疗。
- 源人群3518例中仅47例(1.3%)因外渗接受酚妥拉明,其中72.4%当时方案一致。
适用人群与场景
- 学术医疗系统10家医院2020年10月至2023年5月所有接受血管升压药输注的住院成人患者。
诊断标准与关键阈值
- 原文未提及外周血管升压药方案的具体剂量上限、时间阈值或外渗判定标准。
处置流程与药物剂量
- 原文未提及外周血管升压药方案的具体药物剂量、给药途径、频次或目标值。
- 确认偏离患者中3例因外渗接受酚妥拉明治疗,原文未提及酚妥拉明剂量、途径或频次。
红旗征与不能漏的情况
- 休克恶化而中心静脉通路尚未建立时,易发生超方案剂量等偏离(79.4%偏离发生于此情境)。
- 外周血管升压药外渗需警惕,确认偏离患者中10例(13.7%)发生外渗,3例需酚妥拉明治疗。
研究设计与关键结果
- 源人群二次分析:47/3518例(1.3%)因外周升压药外渗接受酚妥拉明,其中72.4%在外渗时方案一致。
证据类型、等级与局限
- 证据类型:回顾性观察研究(电子病历数据),非随机对照。
对床旁实践的改变
- 外周血管升压药方案总体安全,临床显著外渗不常见,支持在等待中心通路期间按方案使用外周升压药。
- 休克恶化等待中心通路时需注意超剂量等方案偏离,并监测外渗;原文未提供具体剂量上限或监测频率。
- 外渗处理可包括酚妥拉明(原文提及3例使用),但原文未给出剂量与用法,不能据此形成推荐。
指南或共识出处
- 原文未提及指南或共识名称;研究发表于Crit Care Explor。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: This study characterized deviations from an institutional peripheral vasopressor protocol and assessed associated extravasation events.
DESIGN: Retrospective observational study of electronic medical records data.
SETTING: Ten hospitals in an academic health system from October 2020 to May 2023.
PATIENTS: All admitted adult patients who received vasopressor infusions.
INTERVENTIONS: Implementation of a peripheral vasopressor protocol in October 2020.
MEASUREMENTS AND MAIN RESULTS: Three thousand five hundred eighteen patients were identified as having received peripheral vasopressors from October 2020 to May 2023, with 1258 patients suspected of having a deviation from the protocol. One hundred sixty-two patients were randomly selected for chart review, and 73 patients had confirmed deviation. Sixty-three (86.3%) exceeded the maximum allowed dose, 23 had multiple simultaneously infusing peripheral vasopressors, 13 had a peripheral vasopressor infusing longer than 24 hours, and 13 received peripheral vasopressin. Most deviations (79.4%) occurred due to worsening shock while waiting for central access. Extravasation occurred in 10 patients (13.7%), with three patients requiring phentolamine treatment. Fifty-six patients (76.7%) subsequently required central access for continued vasopressor support. In a secondary analysis of the original source population, 47 of 3518 patients (1.3%) received phentolamine for peripheral vasopressor extravasation, of whom the majority (72.4%) were protocol concordant at the time of extravasation.
CONCLUSIONS: Deviations from a peripheral vasopressor protocol primarily involved exceeding the protocol dose limit in the setting of worsening shock while awaiting central access. Clinically significant extravasations were infrequent even among patients with protocol deviations and most treated extravasations occurred in protocol-concordant patients, supporting the overall safety of peripheral vasopressors.
参考来源
- Shyu D, Ingraham NE, McCarville B, et al. A Descriptive Overview of Deviations From an Institutional Peripheral Vasopressor Protocol and Its Effects on Safety Across an Academic Health System. Crit Care Explor. 2026. PMID: 42640631. doi:10.1097/CCE.0000000000001469
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。